secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001193125-23-065289
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q4 net loss of $27.1M; licenses CLN-418; cash runway into 2026
--------------------------------------------------------------------------------

- Cash and investments $550.1M as of Dec 31, 2022; cash runway expected into 2026.
- Licensed U.S. rights to CLN-418 from Harbour Biomed for $25M upfront, up to $563M milestones plus royalties.
- Q4 net loss before noncontrolling interest $27.1M; full-year net income $109.2M due to gain on sale of Cullinan Pearl.
- IND clearance for CLN-978 (CD19xCD3) in Jan 2023; IND filed for CLN-617 (IL-12/IL-2) in Feb 2023.
- Initial clinical data for CLN-049 and CLN-619 expected mid-2023; pivotal study for zipalertinib initiated Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/0001193125-23-065289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/d481993d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-065289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer